Income inequalities, tumor stage at diagnosis, and treatment in patients with non-small cell lung cancer: A population-based study in the Netherlands.

This study investigated the association between income, tumor stage, and treatment in non-small cell lung cancer (NSCLC) patients, stratified by Eastern Cooperative Oncology Group performance status (ECOG-PS). Patients diagnosed with NSCLC between 2017 and 2022 were selected from the Netherlands Cancer Registry (N = 71,025). Median household income at postal code level served as a proxy for income. Logistic regression was used to investigate the association between income, tumor stage at diagnoses and treatment. All analyses were stratified by ECOG-PS (PS0-1 vs. PS2+). Patients with an intermediate or higher income were more likely to be diagnosed with a stage IV tumor compared with those with a lower income. This was seen in patients with PS0-1 (odds ratio [OR]: 1.13 [95% confidence interval [95% CI]: 1.08-1.18], OR: 1.23 [1.18-1.29]) and PS2+ (OR: 1.19 [1.11-1.27], OR: 1.30 [1.19-1.41]). In patients with PS0-1 and a stage II or III tumor, those with an intermediate or higher income more often received a cancer treatment (stage II OR: 1.47 [1.09-1.99], OR: 1.54 [1.13-2.11], stage III OR: 1.20 [1.03-1.40], OR: 1.30 [1.09-1.55]). In patients with PS0-1 and a stage IV tumor, those with an intermediate or higher income more often received immunotherapy (OR: 1.10 [1.02-1.19], OR: 1.30 [1.20-1.41]) and systemic treatment (OR: 1.29 [1.20-1.39], OR: 1.50 [1.37-1.63]). The latter was also found in patients with PS2+ (OR: 1.22 [1.08-1.38], OR: 1.42 [1.23-1.64]). We thereby showed that even in a country with a universal healthcare system, large differences can be seen in the treatments of NSCLC patients according to income.